» Articles » PMID: 29458213

Selective Targeting and Degradation of Doxorubicin-loaded Folate-functionalized DNA Nanocages

Overview
Journal Nanomedicine
Publisher Elsevier
Date 2018 Feb 20
PMID 29458213
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Selective targeting is a crucial property of nanocarriers used for drug delivery in cancer therapy. We generated biotinylated octahedral DNA nanocages functionalized with folic acid through bio-orthogonal conjugation chemistry. Molecular modelling indicated that a distance of about 2.5 nm between folic acid and DNA nanocage avoids steric hindrance with the folate receptor. HeLa cells, a folate receptor positive tumour cell line, internalize folate-DNA nanocages with efficiency greater than 40 times compared to cells not expressing the folate receptors. Functionalized DNA nanocages are highly stable, not cytotoxic and can be efficiently loaded with the chemotherapeutic agent doxorubicin. After entry into cells, doxorubicin-loaded nanoparticles are confined in vesicular structures, indicating that DNA nanocages traffic through the endocytic pathway. Doxorubicin release from loaded DNA cages, facilitated by low pH of endocytic vesicles, induces toxic pathways that, besides selectively killing folate receptor-positive cancer cells, leads to cage degradation avoiding nanoparticles accumulation inside cells.

Citing Articles

DNA-Based Nanostructured Platforms as Drug Delivery Systems.

Kumar M, Jha A, Mishra B Chem Bio Eng. 2025; 1(3):179-198.

PMID: 39974200 PMC: 11835166. DOI: 10.1021/cbe.3c00023.


DNA-based nanostructures for RNA delivery.

Wu Y, Luo L, Hao Z, Liu D Med Rev (2021). 2024; 4(3):207-224.

PMID: 38919398 PMC: 11195427. DOI: 10.1515/mr-2023-0069.


Folate-Functionalization Enhances Cytotoxicity of Multivalent DNA Nanocages on Triple-Negative Breast Cancer Cells.

Unida V, Vindigni G, Raniolo S, Stolfi C, Desideri A, Biocca S Pharmaceutics. 2022; 14(12).

PMID: 36559104 PMC: 9786333. DOI: 10.3390/pharmaceutics14122610.


Application Perspectives of Nanomedicine in Cancer Treatment.

Hou S, Hasnat M, Chen Z, Liu Y, Ashraf Baig M, Liu F Front Pharmacol. 2022; 13:909526.

PMID: 35860027 PMC: 9291274. DOI: 10.3389/fphar.2022.909526.


Development, Therapeutic Evaluation and Theranostic Applications of Cubosomes on Cancers: An Updated Review.

Almoshari Y Pharmaceutics. 2022; 14(3).

PMID: 35335975 PMC: 8954425. DOI: 10.3390/pharmaceutics14030600.